Cost-effectiveness analysis of IEV drug regimen versus ESHAP drug regimen for the patients with Hodgkin and Non-Hodgkins lymphoma in Iran.

Chemotherapy for lymph node cancer is often composed of several drugs that are used in a treatment program. The aim of this study was to perform a cost-effectiveness analysis of IEV drug regimen (Ifosfamide, Epirubicin and Etoposide) versus ESHAP drug regimen (etoposide, methylprednisolone, high-dose cytarabine and cisplatin) in patients with lymphoma in the south of Iran. This was a cost-effectiveness analysis conducted in patients who were admitted to hospital in the south of Iran from 2014 to 2017.